Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG005 combined with etoposide and cisplatin in advanced neuroendocrine carcinoma
CTR20241328Phase 2Active
- Sponsor
- Zelgen
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started May 2024; status: active.
02
Drugs
nilvanstomig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20241328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241328.